logo

Moleculin Biotech Inc (MBRX)



Trade MBRX now with
  Date
  Headline
11/11/2021 8:09:46 AM Moleculin Biotech Q3 Loss/shr $0.15 Vs. Loss/shr $0.33 Prior Year
10/19/2021 9:16:10 AM Moleculin Gets Authorization From UK's MHRA To Commence Phase 1a Trial Of WP1122 For Treatment Of COVID-19
10/18/2021 8:27:22 AM Moleculin Announces Interim Data In Phase 1b/2 Clinical Trial Of Annamycin For Soft Tissue Sarcoma Lung Metastases
7/13/2021 8:36:30 AM Moleculin Receives Approval To Extend Dose Escalation In Phase 1/2 European Trial Evaluating Annamycin For AML
6/21/2021 9:08:25 AM Moleculin Biotech Commences Enrollment And Doses First Subject In Its U.S. Phase 1b/2 Clinical Trial On Annamycin
5/25/2021 9:08:21 AM Moleculin Gets Clearance To Begin Phase 1b/2 Clinical Trial Evaluating Annamycin For Treatment Of STS Lung Metastases
5/12/2021 7:38:18 AM Moleculin Biotech Q1 Net Loss $4.4 Mln Vs. Net Loss $1.2 Mln Last Year
4/14/2021 7:39:23 AM Moleculin Bags New Rare Pediatric Disease Designation From FDA For WP1066 For Treatment Of Ependymoma
4/6/2021 7:32:48 AM Moleculin Biotech Announces Engagement Of IQVIA Biotech To Manage Potential Clinical Trials Of WP1122 For COVID-19
3/30/2021 7:32:12 AM Moleculin Receives FDA Approval Of Fast Track Designation For Annamycin In Sarcoma Lung Metastases
3/24/2021 7:33:40 AM Moleculin Biotech 2020 Net Loss Widens To $17.4 Mln From $4.1 Mln In Prior Year